SCHEMBL1721084

SCHEMBL1721084

Cc1[nH]c(=O)c2ccccc2c1C(C)(C)N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 12/20 0.45
▸ TNKS2 Q9H2K2 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ TNKS O95271 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ PARP15 Q460N3 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ GPR3 P46089 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ GAA P10253 2/20 0.41
▸ PDE4A P27815 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ PDE3B Q13370 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25004045 0.85 PARP1 (0.47) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL29914858 0.69 MEN1 (0.47) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL29914921 0.69 PARP1 (0.47) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL2673475 0.69 PARP1 (0.47) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL917825 0.69 SERPINE1 (0.58) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL3081936 0.66 PARP1 (0.71) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL30472331 0.66 NR4A2 (0.48) PARP1KDM4EALDH1A1MEN1LMNA
SCHEMBL29031850 0.66 NR4A2 (0.48) PARP1KDM4EALDH1A1MEN1LMNA
SCHEMBL7823681 0.66 KDM4E (0.51) PARP1TNKS2KDM4ETNKSALDH1A1
SCHEMBL28601441 0.66 KDM4E (0.50) PARP1TNKS2KDM4ETNKSALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 — — US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 — — US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 — — EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 — — EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 — — US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885TNKS2 282/4885KDM4E 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback